Section Review: Anti-infectives: The potential of novel antifungal drugs for the treatment of disease in the immunocompromised host

References

• WARNOCK DW, RICHARDSON MD: Fungal Infection in theCompromised Patient. (2nd Ed.). John Wiley, Chichester (1991).
   Google Scholar
• MORRISON VA, HAAKE RJ, WEISDORF DJ: Non-Candidafungal infections after bone marrow transplantation: risk factors and outcome. Am. J. Med. (1994) 96:497–503.
   PubMed Web of Science ®Google Scholar
• DUPONT B, DENNING DW, MARRIOTT D, SUGAR A, VIVI-AN! MA, SIRISANTHANA T: Mycoses in AIDS patients. J. Med. Vet. Mycol. (1994) 32\(Suppl. 1):65–77.
   Google Scholar
• ARMSTRONG D: Treatment of opportunistic fungal in-fections. Clin. Infect. Dis. (1993) 16:1–9.
   PubMed Web of Science ®Google Scholar
• LYMAN CA, WALSH TJ: Systemically administered anti-fungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs (1992) 44:9–35.
   Google Scholar
• CLARK AM: The need for new antifungal drugs. In: New Approaches for Antifungal Drugs. Fernandes PB (Ed.). Birk-hauser, Boston (1992):1–19. Far-sighted review of the current situation.
   Google Scholar
• HUNTER PA: Review of antifungal patents appearing •January to June 1993. Exp. Opin. Then Patents (1994)4:131-137. Critical description of fifty-four patents.
   Google Scholar
• HECTOR RF: Review of antifungal patents appearing July 0 1993 to March 1994. Exp. Opin. Ther. Patents (1994)4:911-916. Critical description of fifty-one patents.
   Google Scholar
• HECTOR RF: Antifungal patent review: March - Novem-
   Google Scholar
• '0ber 1994. Exp. Opin. 7ber. Patents (1995) 5:157-161.Critical description of thirty-eight patents.
   Google Scholar
• GOODAY GW: Cell membrane. In: The Growing Fungus. Gow NAR, Gadd GM (Eds.). Chapman and Hall, London (1994):63–74.
   Google Scholar
• BOWMAN BJ, BORGESON CE, BOWMAN EJ: Compositionof Neurospora crassa vacuolar membranes and com-parison to endoplasmlc reticulunn, plasmalemma and mitochondrial membranes. Exp. Mycol. (1987) 11:197–205.
   Google Scholar
• BRA LIBURG J, POWDERLY WG, KOBAYASHI GS, MEDOFFG: Arnphotericin B: current understanding of mecha-nisms of action. Antimicrob. Agents Chemother. (1990) 34:183–188.
   PubMedGoogle Scholar
• BOLARD J, LEGRAND P, HEITZ F, CYBULSKA B: One-sided action of Amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry (1991) 30:5707–5715.
   PubMed Web of Science ®Google Scholar
• SAROSI GA: Amphotericin B, still the 'gold standard' for antifungal therapy. Postgrad. Med. (1990) 88:151–156.
   PubMed Web of Science ®Google Scholar
• HAY RJ: Antifungal drugs on the horizon. J. Amer. Acad. Dermatol. (1994) 31:S82–S85.
   Google Scholar
• HOEPRICH PD, FLYNN NM, KAWACHI MM, LEE KK, LAWRENCE R, HEATH LK, SCHAFFNER CP: Treatment of fungal infections with semisynthetic derivatives of Am-photericin B. Ann. IVY Acad. Sci. (1988) 544:517–546.
   PubMedGoogle Scholar
• HUNTER PA: New developments in non-azole antifun-gals for human disease. In: Fifty Years of Antimicrobials: Past Perspectives and Future Trends. Hunter PA, Darby GK, Russell NJ (Eds.). Cambridge University Press, Cambridge (1995):19–51. A look to the future, with a historical perspective.
   Google Scholar
• BENNETT JE: Developing drugs for deep mycoses: a short history. In: New Strategies in Fungal Disease. Bennett JE, Hay RJ, Peterson PK (Eds.). Churchill Livingstone, Edin-burgh (1992):3–13.
   Google Scholar
• RYDER NS: Squalene epoxidase - enzymology and inhi-bition. In: The Biochemistry of Cell Walls and Membranes in Fungi. Kuhn PJ, Trinci APJ, Jung MJ, Goosey MW, Copping LG (Eds.). Springer, Berlin (1990):189–203.
   Google Scholar
• VANDEN BOSSCHE H: Importance and role of sterols in fungal membranes. In: The Biochemistry of Cell Walls and Membranes in Fungi. Kuhn PJ, Trinci APJ, Jung MJ, Goosey MW, Copping LG (Eds.). Springer, Berlin (1990):135–157.
   Google Scholar
• BAILEY EM, KRAKOVSKY DJ, RYBACK MJ: The triazol antifungal agents: A review of itraconazole and flucona-zole. Pharrnacotherapy (1990) 10:146–153.
   PubMed Web of Science ®Google Scholar
• MATSUKUMA S, OHITSUKA T, KOTAKI H, SHIRA H, SANO T, WATANABE K, NAKAYAMA N, ITEZONO Y, FUJIU M, SH1MMA N, YOKOSE K, OKUDA T: Anew series of natural antifungals that inhibit P450 lanosterol C-14 demethy-lase. L Taxonomy, fermentation, isolation and struc-tural elucidation. J. Antibiot. (1992) 45:151–159.
   Google Scholar
• AOKI Y, YAMAZAKI T, KUNDOH M, SUDOH Y, NAKAYAMA N, SEKINE Y, SHIMADU H, ARISAWA M: A new series of natural antifungals that inhibit P450 lanosterol demethylase.11. Mode of action. J. Antibiot. (1992) 45:160–170.
   PubMed Web of Science ®Google Scholar
• MERCER EL Morpholine antifungals and their mode of action. Biochem. Soc. Trans. (1991) 19:788–793.
   PubMed Web of Science ®Google Scholar
• BOYLE SM, SZANISZLO PJ, NOZAWA Y, JACOBSON ES, COLE GT: Potential molecular targets of metabolic path-ways. J. Med. Vet. Mycol (1994) 32\(Suppl. 1):79–89.
   Google Scholar
• GEORGOPAPADAKOU NH: Chitin synthase as a chemotherapeutic target. In: Emerging Targets in Antibac-terial and Antifungal Chemotherapy. Sutcliffe JA, Georgopa-padakou NH (Eds.). Chapman & Hall, New York (1994:476–494.
   Google Scholar
• GOODAY GW: Chitin metabolism: a target for antifungal and antiparasitic drugs. In: Molecular Aspects of Chemo-therapy. Borowski E, Shugar D (Eds.). Pergamon, New York (1990):175–185.
   Google Scholar
• GOODAY GW: Inhibition of chitin metabolism. In: The Biochemistry of Cell Walls and Membranes in Fungi. Kuhn PJ, Trinci APJ, Jung MJ, Goosey MW, Copping LG (Eds.). Springer, Berlin (1990):61–79.
   Google Scholar
• ZHU W-Y, GOODAY GW: Effects of nikkomycin and echinocandin on differentiated and undifferentiated mycelia of Botrytis cinerea and Mucor rouxii. Mycol. Res. (1992) 96:371–377.
   Google Scholar
• MILEWSKI S, MIGNINI F, BOROWSKI E: Synergistic action of nikkomycin X/Z with azole antifungals on Candida albicans. J. Gen. Microbiol. (1991) 137:2155–2161.
   PubMedGoogle Scholar
• HECTOR RF, SCHALLER K: Positive interaction of nikkomydns with azoles against Candida albicans in vitro and in vivo. Antimicrob. Agents Chemother. (1992) 36:1284–1289.
   PubMed Web of Science ®Google Scholar
• BECKER JM, NA1DER F: Fungal peptide transport as a drug delivery system, In: Peptide Based Drug Design: Controlling Transport and Metabolism. Taylor M, Amidon G (Eds.). American Chemical Society, Washington DC (1995):369–384.
   Google Scholar
• BULAWA CE: Genetics and molecular biology of chitin synthesis in fungi. Ann. Rev. Microbiol. (1993) 47: 505–534.
   PubMed Web of Science ®Google Scholar
• GOODAY GW: Cell walls. In: The Growing Fungus. Gow NAR, Gadd GM (Eds.). Chapman and Hall, London (1994):43–62.
   Google Scholar
• GOW NAR, SWOBODA R, BERTRAM G, GOODAY GW, BROWN APJ: Key genes in the regulation of dimorphism In Candida albicans. In. Dimorphic Fungi in Biology and Medicine. Vanden Bossche H, Odds FC, Kerridge D (Eds.). Plenum Press, New York (1993):61–71.
   Google Scholar
• SAXENA IM, BROWN RM, FEVRE M, GEREMIA RA, HENRIS-SAT B: Multidomain architecture of 13-ghicosyl trans-ferases: implications for mechanism of action. J. Bact. (1995) 177:1419–1424.
   PubMed Web of Science ®Google Scholar
• MILEWSKI S, CHMARA H, BOROWSKI E: Antibiotic tetaine- a selective inhibitor of chitin and mannoprotein synthesis in Candida albicans. Arch. Microbiol. (1986) 145:234–240.
   PubMed Web of Science ®Google Scholar
• MILEWSKI S, CHMARA H, ANDRUSZKIEWICZ R, BOROWSKI E: Synthetic derivatives of N3-fumaroyl-L-2,3-diaminopropanoic add inactivate glucosamine syn-thetase from Candida albicans. Biochint. Biophys. Acta (1986) 828:247–254.
   Web of Science ®Google Scholar
• MILEWSKI S, ANDRUSK1EWICZ R, KASPRZAK L, MAZERSKIJ, MIGNINI F, BOROWSKI E. Mechanism of action of anticandkial dipeptides containing inhibitors of glu-cosamine-6-phosphate synthase. Antimicrob. Agents Chemother. (1991) 35:36–43.
   PubMed Web of Science ®Google Scholar
• GOODAY GW, ZHU W-Y, O'DONNELL RW: What are the roles of chitinases in the growing fungus? FEMS Micro-biol. Lett. (1992) 100:387–392.
   Google Scholar
• SAKUDA S, NISHIMOTO Y, OHI M, WATANABE M, TAKAYAMA S ISOGAI A, YAMADA Y: Effects of demethyl-allosamidin, a potent yeast chitinase inhibitor, on cell division in yeast. Agric. Biol. Chem. (1990) 54:1333–1335.
   Web of Science ®Google Scholar
• NISHIMOTO Y, SAKUDA S, TAKAYAMA S, YAMADA Y: Isolation and characterization of new allosamidins. J. Antibiot. (1991) 44:716–722.
   PubMed Web of Science ®Google Scholar
• KATO T, SHIZURI Y, IZUMIDA H, YOKOYAMA A, ENDO M: Styloguanidines, new chitinase inhibitors from the marine sponge Stylotella aurantium. Tetrahedron Lett. (1995) 36:2133–2136.
   Web of Science ®Google Scholar
• HECTOR RE: Compounds active against cell walls of ••medically important fungi Clin. Microbiol. Rev. (1993)6:1-21. DEBONO M, GORDEE RS: Antibiotics that inhibit fungal cell wall development. Ann. Rev. Microbiol. (1994) 48:471–497.
   Google Scholar
• GEORGOPAPADAKOU NH, TKACZ JS: The fungal cell wall esas a drug target. Trends Microbiol. (1995) 3:98-104. Three excellent reviews of the cell wall as a target, covering chitin, glucan and mannoprotein metabolism. BALKOVEC JM: Lipopeptide antifungal agents. Exp. Opin. Invest. Drugs (1994) 3:65–82.
   Google Scholar
• DEBONO M: The echinocandins: antifungals targeted to isthe fungal cell wall. Exp. Opin. Invest. Drugs (1994) 3:821-829. Two reviews, from different perspectives, of the most promising group of new compounds.
   Google Scholar
• KURTZ MB, DOUGLAS C, MARRINAN J, NOLLSTADT K, ONISH1 J, DREIKORN S, MCMANUS OB, GARCIA ML: In-creased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhi-bition of cell wall synthesis. Antimicrob. Agents Chemother. (1994) 38:2750–2756.
   PubMed Web of Science ®Google Scholar
• BEAULIEU D, TANG J, VESSELS JM, RADDING JA, PARR TR: Characterization and cilofungin inhibition of solu-bilized Aspergillus fumigatus (1,3)-13-D-glucan-syn-thase. Antimicrob. Agents Chemother. (1994) 38:937–944.
   PubMed Web of Science ®Google Scholar
• GORDEE RS, DEBONO M, PARR TR: The fungal cell wall - a target for lipopeptide antifungal agents. In: New Approaches for Antifungal Drugs. Femandes BP (Ed.). Birk-hauser, Boston (1992):46–63.
   Google Scholar
• POWLES MA, MCFADDEN DC, LIBERATOR PA, ANDERSON JW, VADAS EB, MEISNER D, SCHMATZ DM: Aerosolized L-693,989 for Pneumocystis carinii prophylaxis in rats. Antimicrob. Agents Chemother. (1994) 38:1397-1401. Interesting approach to this problem.
   Google Scholar
• KURTZ MB, HEATH IB, MARRINAN J, DREIKORN S, ONISHIJ, DOUGLAS C: Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-13-glucan synthase. Antimicrob. Agents Chemother. (1994) 38:1480–1489.
   PubMed Web of Science ®Google Scholar
• NOLLSTADT ICH, POWLES MA, FUJIOKA H, AIICAWA M,SCHMATZ DM: Use of 1,3-13-glucan-spec1f1c antibody to study the cyst wall of Pneumocystis carinii and effects of pneumocandin Bo analog L-733,560. Antimicrob. Agents Chemother. (1994) 38:2258–2265.
   PubMed Web of Science ®Google Scholar
• AOKI M, ANDOH T, UEKI T, MASUYOSHI S, SUGAWARAK, OKI T: BU-4794F, anew 1,3-13-glucan synthase inhibi-tor. J. Antibiot. (1993) 46:952–960.
   PubMed Web of Science ®Google Scholar
• VANMIDDLESWORTH FL, OMSTEAD MN, SCHMATZ D, BARTIZAL K, FROMTLING R, BILLS G, NOLLSTADT ICH, HONEYCUTT S, ZIWEEINK M, GARRITY G, WILSON K: L-687,781, a new member of the papulacandin family of 1,3-13-D-glucan synthase inhibitors. L Fermentation, isolation, and biological activity. J. Antibiot. (1993) 44:45–51.
   Google Scholar
• DAVILA T, SAN-BIAS G, SAN-BIAS F: Effect of papula-candin B on glucan synthesis in Paracoccidiodes brasiliensis. J. Med. Vet. Mycol. (1986) 24:193–202.
   PubMedGoogle Scholar
• JAMES PG, CHERNIAK R, JONES RG, STORTZ CA, REISS E: Cell wall ghicans of Ctyptococcus neoformans CAP 67. Carb. Res. (1990) 198:23–38.
   PubMed Web of Science ®Google Scholar
• GALGIANA JN, SUN SH, CLEMONS KV, STEVENS DA: Activ-ity of cikdungin against Coccidioides immitis. Differen-tialin vitro effects on mycelia and spherules correlated with in vivo studies. J. Infect. Dis. (1990) 162:944–948.
   Google Scholar
• BUSSEY H, BOONE C, BROWN J, HILL K, ROEMER, SDICU A-M: (1–6)-0-glucan biosynthesis: potential targets for antifungal drugs. In: New Approaches for Antifungal Drugs. Fernandes PB (Ed.). Birkhuser, Boston (1992):20–31.
   Google Scholar
• OKI T: Praditnicin, a novel antifungal agent. In: New Approaches for Antifungal Drugs. Fernandes PB (Ed.). Birk-huser, Boston (1992):64–87.
   Google Scholar
• FUNGTOMC JC, MINASSIAN B, HUCZKO E, KOLEK B, BONNER DP, KESSLER RE: In vitro antifungal and fungi-cidal spectra of a new pradimicin derivative BMS-181184. Antimicrob. Agents Chemother. (1995) 39:295–300.
   Google Scholar
• SAWADA Y, NUMATA K, MURAKAMI T, TANIMICHI H, YAMAMOTO S, OKI T: Calcium-dependent anticandidal action of pradhzulcin A. J. Antibiot. (1990) 43:715–720.
   PubMed Web of Science ®Google Scholar
• UEKI T, NUMATA K, SAWADA Y, NISHIO M, OHKUMA H, TODA S, KAMACHI H, FUKUGAWA Y, OKI T: Studies on the mode of antifungal action of pradimicin antibiotics IL D-Mannopyranoside-binding site and calcium-bind-ing site. J. Antibiot. (1993) 46:455–464.
   PubMed Web of Science ®Google Scholar
• OKI T, TENMAYO 0, HIRANO M, TOMATSU K, KAMEI H: Pradimicins A, B, and C: new antifungal antibiotics In vitro and in vivo biological activities. J. Antiblot. (1990) 43:763–770.
   PubMed Web of Science ®Google Scholar
• YASUOKA A, OKA S, KOMURO K, SHIMIZU H, KITADA K, NAICAMURA Y, SHIBAHARA S, TAKEUCHI T, KONDO S, SHIMADA K, KIMURA S: Successful treatment ofPneismo-cystis carinii pneumonia in mice with benanomicin A (ME1451). Antimicrob. Agents Chemother. (1995) 39:720-724. Demonstrates the potential of pradimicins and benanomicins as antifungal agents.
   Google Scholar
• DE NOBEL H, LIPICE PN: Is there a role for GPIs in yeastcell-wall assembly? Trends Cell Biol. (1994) 4:42–45.
   Google Scholar
• GAZALBO D, ELORZA MV, SANJUAN R, MARCILLA AM, VALENTIN E, SENTANDREU R: Critical steps in fungal cell wall synthesis: strategies for their inhibition. Pharma-col. Then (1993) 60:337–345.
   PubMed Web of Science ®Google Scholar
• YAMAKI H, YAMAGUCHI M, IMAMURA H, SUZUKI H, NISHIMURA T, SAITO H, YAMAGUCHI H: The mechanism 99 of action of (S)-2-amino-4-oxo-5-hydroxypentanoic acid, RI-331: the inhibition of homoserine dehydro-genase in Saccharomyces cerevisiae. Biochem. Biophys. Res. Comm. (1990) 168:837–843.
   Google Scholar
• BRUMMER E, CASTANEDA E, RESTREPO A: Paracoccidio-domycosis: an update. Clin. Microbiol. Rev. (1993) 42:89–117.
   Google Scholar
• MONK BC, PERLIN DS: Fungal plasma membrane protonpumps as promising new antifungal targets. Crit. Rev. Micro biol. (1994) 20:209–223.
   PubMed Web of Science ®Google Scholar
• RINGROSE PS: Warhead delivery and suicide substratesas concepts in antimicrobial drug design. In: The Scien-tific Basis of Antimicrobial Chemotherapy. Greenwood D, O'Grady F (Eds.). Cambridge University Press, Cambridge (1985):219–266.
   Google Scholar
• HIGGINS CF: Synthesizing designer drugs. Nature (1987)327:655–656.
   PubMed Web of Science ®Google Scholar
• BASRAI MA, ZHANG H-L, MILLER D, NAIDER F, BECKER JM:Toxicity of oxalysine and oxalysine-containing pep-tides against Candida albicans: regulation of peptide transport by amino acids. J. Gen. Microbiol. (1992) 138:2333–2362.
   Google Scholar
• VAN DEN BOSSCHE H, MARICHAL P, ODDS FC: Molecular mechanisms of drug resistance in fungi. Trends Micro-biol. (1994) 2:393-400. Excellent review of current problems with resistance.
   Google Scholar
• FIGGITT DP, DENYER SP, DEWICK PM, JACKSON DE, WILLIAMS P: Topoisomerase II: a potential target for novel antifungal agents. Biochem. Biophys. Res. Comm. (1989) 160:257–262.
   PubMed Web of Science ®Google Scholar
• JACKSON DE, FIGGITT DP, DENYER SP: TopoisomeraseII inhibitors: prospects for new antifungal agents. In: Emerging Targets in Antibacterial and Antifungal Chemo-therapy. Sutcliffe JA, Georgopapadakou NH (Eds.). Chapman and Hall, New York (1992):374–392.
   Google Scholar
• BIRSE C, FONZI WA, SAPORITO S, IRWIN M, SYPHERD PS:Molecular genetics of dimorphism in Candida albicans. In: New Strategies in Fungal Disease. Bennett JE, Hay RJ, Peterson PK (Eds.). Churchill Livingstone, Edinburgh (1992):133–152.
   Google Scholar
• COLTHURST DR, SANTOS M, GRANT CM, TUITE MF: Can-dida albicans and three other Candida species contain an elongation factor structurally and functionally analogous to elongation factor 3. FEMS Microbiol. Lett. (1991) 80:45–50.
   Web of Science ®Google Scholar
• CHAKRABURTTY K: Elongation factor 3 - a unique fungalprotein. In: New Approaches for Antifungal Drugs. Fernan-des PB (Ed.). Birkhuser, Boston (1992):114–142.
   Google Scholar
• WALTERS DR: Inhibition of polyamine biosynthesis in fungi_ Mycol. Res. (1995) 99:129–139.
   Google Scholar
• GRUHN CM, BOYLE SM: Biochemical and morphological effects of polyainine synthesis inhibitors on Trichophy-ton andMicrosporum. J. Med. Vet. Mycol. (1991) 29:63–72.
   PubMedGoogle Scholar
• PFALLER MA, GERARDEN T, RILEY J: Growth inhibition of pathogenic yeasts by a-difluoromethylornithine: an Inhibitor of orrulthine decarboxylase. Mycopathologia (1987) 98:3–8.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, RILEY J, GERARDEN T: Polyamine depletionand growth inhibition of Cryptococcus neoformans by a-diftuoromethylomithine and cyclohexylamine. My-copathologia (1990) 112:27–32.
   PubMedGoogle Scholar
• LEVITZ SM, DIBENEDETTO DJ, DIAMOND RD: Inhibitionand killing of fungi by the polyamine-oxidase system. Antifungal activity of the PAO-polyamine system. An-tonie van Leewenhoek (1990) 58:107–114.
   PubMed Web of Science ®Google Scholar
• MARESCA B, BENNETT J, FONZI W, HITCHCOCK CA, LODGE JK, WILLIAMSON PR: Molecular approaches to identify novel targets for future development of anti-fungal agents. J. Med. Vet. Mycol. (1994) 32\(Suppl. 1):287–298.
   Google Scholar
• WHEELER MH, BELL AA: Melanins and their importanceIn pathogenic fungi. Curr. Top. Med. Mycol. (1988) 2:338–387.
   PubMedGoogle Scholar
• OKADA H, YAMAMOTO K, TSUTANO S, INOUYE Y, NAKA-MLTRA S, FURUKAWA J: A new group of antibiotics, hydroxamic acid antlmycotic antibiotics. IL The struc-ture of neoenactins NIA and NL2 structure-activity rela-tionship. J. Antibiot. (1989) 42:276–282.
   Google Scholar
• DOBBIN PS, HIDER RC, HALL AD, TAYLOR PD, SARPONGP, PORTER JB, XIAO GY, VAN DER HELM D: Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential J. Med. Chem. (1993) 36:2448–2458.
   Web of Science ®Google Scholar
• BOELAERT JR, DE LOCHT M, VAN CUTSEM J, KERRELS V,CANTINIEAUX B, VERDONCK A, VAN LANDUYT HW, SCHNEIDER YJ: Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J. Clin. Invest. (1993) 91:1979–1986.
   PubMed Web of Science ®Google Scholar
• CAPOBIANCO JO, LERNER CG, GOLDMAN RC: Applicationof a fluorogenic substrate assay in the assay of pro-teolytic activity and in the discovery of a potent inhibi-tor of Candida albicans aspartic proteinase. Anal. Biochem. (1992) 204:96–102.
   PubMed Web of Science ®Google Scholar
• BARRETT-BEE K, HAYES Y, WILSON RG, RYLEY JF: Acomparison of phospholipase activity, cellular adher-ence and pathogenicity of yeasts. J. Gen. Microbiol. (1985) 131:1217–1221.
   PubMedGoogle Scholar
• JENKINSON FEE, SHEPHERD MG: A mutant of Candidaalbicans deficient in P-N-acetylglucosaminidase (chito-biase). J. Gen. Microbiol. (1987) 133:2097–2106.
   PubMedGoogle Scholar
• VON WARTBURG A, TRABER R: Chemistry of natural cyclosporin metabolites. In: Cidosporin. Borel JF (Ed.). Karger, Basel (1986):28–45.
   Google Scholar
• HODGSON J: Data directed drug design. Biotechnology (1991) 34:19–21.
   Google Scholar
• RUSSELL PE, MILLING RJ, WRIGHT K: Control of fungipathogenic to plants. In: Fifty Years of Antimicrobials: Past Perspectives and Future Trends. Hunter PA, Darby GK, Russell NJ (Eds.). Cambridge University Press, Cambridge (1995):85–110.
   Google Scholar
• FUJIMURA M, KAMAKURA T, INOUE H, INOUE S, YAMA-GUCHI I: Sensitivity of Neurospora crassa to benzimi-dazoles and N-phenylcarbamates: effect of amino acid substitutions at position 198 in fl-tubulin. Pest. Biochem. Physiol. (1992) 44:165–173.
   Web of Science ®Google Scholar
• GOODAY GW, ADAMS DJ: Sex hormones and fungi. Adv. Microb. Physiol (1993) 34:69-145. CANNON RD, TIMBERLAKE WE, GOW NAR, BAILEY D, BROWN A, GOODAY GW, HUBE B, MONOD M, NOMBELA C, NAVARRO F, PEREZ R, SANCHEZ M, PIA J: Molecular biological and biochemical aspects of fungal dimor- phism. J. Med. Vet. Mycol. (1994) 32\(Suppl. 1):53–64.
   Google Scholar
• BUCHAN ADB, KELLY VA, KINSMAN OS, GOODAY GW, G OW NAR: Effect of trifluoperazine on growth, morpho-genesis and pathogenicity of Candida albtcans. J. Med. Vet. Mycol. (1993) 3:427433.
   Google Scholar
• FUJIKAWA A, IN Y, INOUE M, ISHIDA T, NF_MOTO N, KOBAYASHI Y, KATAOKA R, IKAI K, TAKESAKO K, KATO I: X-Ray and NMR conformational study of aureobasidin E: a cyclic depsipeptide with potent antifungal activity. J Org. Chem. (1994) 59:570–578.
   Web of Science ®Google Scholar
• MAGET-DANA R, PEYPOUX F: Iturins, a special class of pore-forming lipopeptides: biological and physico-chemical properties. Toxicology. (1994) 87:151–174.
   PubMed Web of Science ®Google Scholar
• ZASLOFF M: Margainins, a class of antimicrobial pep-tides from Xenopus skin: Isolation, characterization of the two active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad. Sc. USA. (1987) 84:5449–5453.
   PubMed Web of Science ®Google Scholar
• FUSETANI N: Antifungal substances from marine inver-tebrates. Ann. IVY Acad. Sci. (1988) 544:113–127.
   PubMedGoogle Scholar
• DEBONO M, GORDEE RS: Drug discovery: nature's ap-proach. In: Chemotherapy of Fungal Disease. J Ryley (Ed.). Springer-Verlag, Berlin (1990):77–109.
   Google Scholar
• DAVIDSON BS, MOLINSK1TF, BARROWS LR, IRELAND CM: Varacin: a novel benzopentathkpin from Lissoclinum vareau that is cytotoxic toward a human colon tumor. J. Am. Chem. Soc. (1991) 113:4709–4710.
   Web of Science ®Google Scholar
• SEARLE PA, MOLINSKI TF: Five new alkaloids from the tropical ascidian, Ltssodinum sp. J. Org. Chem. (1994) 59:6600–6605.
   Web of Science ®Google Scholar
• COMPAGNONE RS, FAULKENER DJ, CARTE BK, CHAN G, FREYER A, HEMLING ME, HOFMAN GA, MATTERN MR: Pentathiepins and trithianes from two Lissoclinum species and a Eudtstarna sp.: inhibitors of protein kinase C. Tetrahedron (1994) 50:12785–12792.
   Web of Science ®Google Scholar
• MOORE KS, WEHRLI S, RODER H, ROGERS M, FORREST JN, MCCRIMMON D, ZASLOFF M: Squalamine: An aminos-terol antibiotic from the shark. Proc. Natl. Acad. Sc. USA. (1993) 90:1354–1358.
   PubMed Web of Science ®Google Scholar
• VANDEN BOSSCHE H, WARNOCK DW, DUPONT B, KER- RIDGE D, SEN GUPTA S, IMPROVISI L, MARICHAL P, ODDS FC, PROVOST F, RONIN 0: Mechanisms and clinical importance of antifungal drug resistance. J. Med. Vet. Mycol. (1994) 32 (Supp1.1):189–202.
   Google Scholar
• RYLEY JF, IIARRETI-BEE K: Screening for antifungal activity. In: Emerging Targets in Antibacterial and Antifun-gal Chemotherapy. Sutcliffe JA, Georgopapadakou NH (Eds.). Chapman and Hall, New York (1992):546–567.
   Google Scholar
• BICKERS DR: Antifungal therapy: potential interactions with other classes of drugs. J. Am. Acad. Dermatol. (1994) 31:S87–S90.
   PubMed Web of Science ®Google Scholar
• CROFT SL: Antiprotozoal drugs: some echoes, some shadows. In: Fifty Years of Antimicrobials: Past Perspectives and Future Trends. Hunter PA, Darby GK, Russell NJ (Eds.). Cambridge University Press, Cambridge 0999:299–326.
   Google Scholar
• RYLEY J: Who needs new antimicrobials? In: Fifty Years of Antimicrobials: Past Perspectives and Future Trends. Hunter PA, Darby GK, Russell NJ (Eds.). Cambridge Univer-sity Press, Cambridge (1995):165–177.
   Google Scholar